Navigation Links
IMAGEQUANT 400 WKSTN from GE Healthcare, formerly Amersham Biosciences

ProductsIMAGEQUANT 400 WKSTN from GE Healthcare, formerly Amersham Biosciences
Company GE Healthcare, formerly Amersham Biosciences
Item IMAGEQUANT 400 WKSTN
Price $41,029.00
Description IMAGEQUANT 400 WKSTN, 1 EA. Category: ImageQuant CCD Imagers.
Info GE Healthcare, formerly Amersham BiosciencesGE Healthcare, formerly Amersham Biosciences
800 Centennial Avenue
PO Box 1327
Piscataway, NJ 08855-1327
USA


For GE Healthcare contacts in other countries
please click here.


Call GE Healthcare, formerly Amersham Biosciences to buy products (US and Canada only; other locations use numbers below)
USA Canada 1-866-461-9198
Customer Service: 732-457-8000
Fax Number: 732-235-2201
Web Site: http://www.gelifesciences.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. IMAGEQUANT 300 IQTL from GE Healthcare, formerly Amersham Biosciences
2. IMAGEQUANT 100 WKSTN from GE Healthcare, formerly Amersham Biosciences
3. IMAGEQUANT 100 IQTL from GE Healthcare, formerly Amersham Biosciences
4. IMAGEQUANT 400 IQTL from GE Healthcare, formerly Amersham Biosciences
5. IMAGEQUANT 300 WKSTN from GE Healthcare, formerly Amersham Biosciences
6. Taq DNA Polymerase (cloned) from GE Healthcare, formerly Amersham Biosciences
7. Taq DNA Polymerase (Thermus aquaticus) from GE Healthcare, formerly Amersham Biosciences
8. Taq DNA Polymerase (Thermus aquaticus) from GE Healthcare, formerly Amersham Biosciences
9. One-Phor-All Buffer PLUS from GE Healthcare, formerly Amersham Biosciences
10. Ready-To-Go T4 DNA Ligase from GE Healthcare, formerly Amersham Biosciences
11. CodeLink Activated Slides from GE Healthcare, formerly Amersham Biosciences
(Date:10/28/2014)... tragic realities of cancer is that the drugs ... their effectiveness varies unpredictably from patient to patient. ... change this reality by rapidly assessing how effective ... cancer before chemotherapy begins. , A team of ... Professor Melissa Skala has developed the technique, which ...
(Date:10/28/2014)... Researchers from the National University of Singapore (NUS) have ... - breeding and laying direct developing eggs in live ... the white spotted bush frog ( Raorchestes chalazodes ... of two species known to adopt this novel reproductive ... of London,s Biological Journal of the Linnean Society ...
(Date:10/27/2014)... University researchers have delivered a scientific one-two punch with ... fibers self-assemble via their sticky ends. , Collagen is ... of bone and the fibrous tissues that support cells ... to better synthetic collagen for tissue engineering and cosmetic ... Hartgerink has been studying synthetic collagen for a decade, ...
Breaking Biology News(10 mins):Improving breast cancer chemo by testing patient's tumors in a dish 2Improving breast cancer chemo by testing patient's tumors in a dish 3NUS researchers discover for the first time that a rare bush frog breeds in bamboo 2NUS researchers discover for the first time that a rare bush frog breeds in bamboo 3'Sticky' ends start synthetic collagen growth 2'Sticky' ends start synthetic collagen growth 3
... team of French and German researchers report in the ... http://www.fasebj.org ) that people with limb-girdle muscular dystrophy are ... to prevent the loss of muscle tissue. By targeting ... protein, scientists could develop new drugs to stop muscle ...
... thing could be harmful to the environment. For years, ... bacteria and, recently, have used this knowledge to create ... Missouri researcher has found that silver nanoparticles also may ... from wastewater treatment systems. The study was funded by ...
... and Canadian scientists expect to begin trials next month (May) ... of energy trapped in the world,s unrecoverable heavy oil deposits. ... because the oil has become either solid or too thick ... conventional means. , However, scientists at Newcastle University, England, and ...
Cached Biology News:Researchers discover molecular basis of a form of muscular dystrophy 2Too much technology may be killing beneficial bacteria 2Scientists aim to boost world energy supplies -- with microbes! 2Scientists aim to boost world energy supplies -- with microbes! 3Scientists aim to boost world energy supplies -- with microbes! 4
(Date:10/30/2014)... 2014) – The severe flooding that devastated a wide ... destructive if the bridges, roads and other infrastructure had ... from the University of Colorado Denver. , "People need ... Jimmy Kim, PhD, associate professor of structural engineering at ... and lead author the study. "There is an assumption ...
(Date:10/27/2014)... WORCESTER, Mass. and TORONTO ... Biotechnology Corporation ( www.generex.com ) (OTCQB: GNBT) today ... the immunological response triggered by its novel proprietary ... of relapse in breast cancer patients. The AE37 ... wholly-owned subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ). ...
(Date:10/27/2014)... Florida (PRWEB) October 27, 2014 ... at reducing and eliminating several types of pediatric ... not been achieved in over 30 years of ... Noah's Light Foundation, proves that one mom's determination ... diagnosed just before Halloween trick-or-treating, and it’s only ...
(Date:10/27/2014)... , October 27, 2014 Investor-Edge ... Inc. (NASDAQ: NBIX ), Insmed Inc. (NASDAQ: ... BCRX ), Dyax Corporation (NASDAQ: DYAX ... these five companies can be accessed at: http://investor-edge.com/register ... NASDAQ Composite ended at 4,483.72, up 0.69%, the Dow ...
Breaking Biology Technology:CU Denver study says upgrading infrastructure could reduce flood damage 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5